2020-03-04T16:46:30-06:00 2019-06-30 930900579 MCDONALD JACOBS PC 520 SW YAMHILL ST STE 500 PORTLAND OR 97204 990 2018-07-01 930571472 NATIONAL PSORIASIS FOUNDATION NATI 5032447404 6600 SW 92ND AVENUE NO 300 PORTLAND OR 97223 RANDY BERANEK PRESIDENT/CEO 5032447404 2020-02-25 1 SANG AHN P00540880 5032270581 50.204.228.78 2020-02-25 20:38:24 PS P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 6C9B1A35775087DBDB8A6D25ECA509C7F6C27838 2018 2020-09-23 17:36:50Z RANDY BERANEK 6600 SW 92ND AVENUE NO 300 PORTLAND OR 97223 18191364 0 X WWW.PSORIASIS.ORG X 1968 OR TO DRIVE EFFORTS TO CURE PSORIATIC DISEASE AND IMPROVE THE LIVES OF THOSE AFFECTED. 15 15 90 10877 1255184 263813 13408527 13168307 753742 1271782 520104 137107 -159762 -361942 14522611 14215254 2381798 2781813 0 0 6072178 5977319 24805 0 2194381 4859707 4666505 13338488 13425637 1184123 789617 10616789 12437744 2918675 3903740 7698114 8534004 X THE NATIONAL PSORIASIS FOUNDATION PROVIDES PEOPLE WITH PSORIASIS AND PSORIATIC ARTHRITIS THE SERVICES THEY NEED TO BEST MANAGE THEIR CONDITION, WHILE PROMOTING RESEARCH TO FIND A CURE. 0 0 4371581 2781813 13251 RESEARCH AND PROFESSIONAL EDUCATIONNPF FUNDED 41 PROJECTS SUPPORTING DISCOVERY, TRANSLATIONAL AND CLINICAL RESEARCH FOR ALL PHASES OF PROFESSIONAL DEVELOPMENT, STUDENT THROUGH ESTABLISHED RESEARCHERS, PROVIDING OVER $2.8 MILLION TO ADVANCE CRITICAL RESEARCH FOR PSORIATIC DISEASE. THESE OFFERINGS INCLUDED IN THE INAUGURAL YEAR OF THE PSA DIAGNOSTIC TEST GRANT WITH THE OBJECTIVE TO DEVELOP A UNIVERSAL, CLINICAL APPLICABLE AND ACCURATE TEST FOR THE DIAGNOSIS OF PSORIATIC ARTHRITIS, AN ADVANCE THAT WOULD BE SO BENEFICIAL TO OUR COMMUNITY. PATIENT-CENTERED RESEARCH ALSO FLOURISHED WITH VALIDATION INITIATION FOR OUR PATIENT DATA PLATFORM, CITIZEN PSCIENTIST, AND IMPROVEMENTS TO OUR ANNUAL SURVEY IN ORDER TO GENERATE MORE ROBUST DATA AND BENEFIT PATIENT PARTICIPANTS. THE JOURNAL OF PSORIASIS AND PSORIATIC ARTHRITIS (JPPA) CONTINUES TO GROW AND BE A RESOURCE FOR PSORIATIC DISEASE INFORMATION. THE BIENNIAL RESEARCH SYMPOSIUM WAS A HUGE SUCCESS WITH OVER 120 ATTENDEES AND KEY EXPERTS DISCUSSING MILESTONES TO A CURE. PROFESSIONAL EDUCATION NPF HELD SEVERAL EDUCATION EVENTS FOR PROFESSIONALS, INCLUDING PRACTICING PHYSICIANS, RESIDENTS, FELLOWS AND ADVANCED PROVIDERS IN DERMATOLOGY AND RHEUMATOLOGY TO PROVIDE THE LATEST INFORMATION ABOUT TREATMENET ADVANCES AND GUIDELINES, KNOWLEDGE OF THE DISEASE AND COMORBIDITIES. THE RESDENTS' MEETING CELEBRATES ITS 20TH YEAR AND REMAINS A CORNERSTONE FOR TRAINNING. A NOVEL PODCAST SERIES WAS LAUNCHED AND CONTINUING MEDICAL EDUCATION WAS ALSO OFFERED THROGUH THE JPPA. 1308848 ADVOCACY THE FOUNDATION'S ADVOCACY PRIORITIES ARE FOCUSED ON STRATEGIES THAT ENSURE INDIVIDUALS LIVING WITH PSORIATIC DISEASES HAVE FAIR AND AFFORDABLE ACCESS TO NEEDED TREATMENTS AND PROMOTE FEDERAL RESEARCH EFFORTS. HARNESSING THE COLLECTIVE EFFORTS OF THOUSANDS OF ADVOCATES, THE PSORIASIS FOUNDATION WORKED THROUGH ADVOCACY EFFORTS AT THE STATE AND FEDERAL LEVEL: TO MAKE INSURANCE FAIR AND AFFORDABLE AND HELP IMPROVE COVERAGE FOR PEOPLE WITH PSORIATIC DISEASE, HELP SET PUBLIC HEALTH POLICY FOR PSORIASIS AND PSORIATIC ARTHRITIS THROUGH THE PASSAGE OF ACCESS TO CARE LEGISLATION AT THE STATE LEVEL, WORKED TO IMPROVE THE SAFETY AND AFFORDABILITY OF PSORIASIS AND PSORIATIC ARTHRITIS TREATMENTS THROUGH FEDERAL REGULATION AND LEGISLATION, AND TO INCREASE FEDERAL FUNDING FOR PSORIASIS AND PSORIATIC ARTHRITIS RESEARCH IN ORDER TO FIND BETTER TREATMENTS AND A CURE. 4546249 3347 EDUCATION, OUTREACH AND PATIENT SERVICES PUBLISHED THE LATEST INFORMATION ON PSORIASIS AND PSORIATIC ARTHRITIS TREATMENTS, RESEARCH AND HEALTHY LIVING FOR 168,000 READERS OF PSORIASIS ADVANCE MAGAZINE, THE ONLY MAGAZINE DEDICATED TO HELPING READERS LIVE WITH PSORIATIC DISEASE.ASSISTED 14,272 PATIENTS THROUGH THE PATIENT NAVIGATION CENTER, WHICH PROVIDES PERSONALIZED AND ONGOING SUPPORT TO PEOPLE AFFECTED BY PSORIATIC DISEASE THROUGH DISEASE AND TREATMENT INFORMATION, HELP FINDING SPECIALISTS AND GUIDANCE ON AFFORDABLE ACCESS TO TREATMENT.PROVIDED COMPREHENSIVE RESOURCES AT WWW.PSORIASIS.ORG AND OTHER SITES FOR 4.9 MILLION UNIQUE VISITORS.SENT EDUCATIONAL E-NEWSLETTERS TO MORE THAN 154,000 SUBSCRIBERS.BROADCASTED 17 PATIENT EDUCATIONAL WEBINARS WITH A TOTAL OF 2,455 ATTENDEES LAUNCHED THE PSOUND BYTESTM PODCAST JANUARY 8, 2019. BROADCAST 28 EPISODES WITH A TOTAL OF 13,207 LISTENS. TWO EPISODES ACHIEVED GOLD STANDARD (AT LEAST 500 LISTENS WITHIN 30 DAYS OR LESS).PROVIDED PERSONAL PEER SUPPORT TO 208 NEW PARTICIPANTS IN THE PSORIASIS ONE TO ONE PROGRAM.HOSTED 2 MORE THAN SKIN DEEP AND 2 KNOW WHAT'S POSSIBLE EDUCATIONAL EVENTS ATTRACTING MORE THAN 100 PARTICIPANTS.ENGAGED 4,593 VOLUNTEERS THROUGH NON-FUNDRAISING PROGRAMS AND EVENTS. 10226678 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 83 0 90 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 X 15 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X JOHN ROGACKI 5032447404 6600 SW 92ND AVENUE NO 300 PORTLAND OR 97223 PETE REDDING CHAIR 1.00 X X 0 0 0 RAYMOND NEWTON CHAIR-ELECT 1.00 X X 0 0 0 CAROL OSTROW VICE-CHAIR 1.00 X X 0 0 0 TERRI THEISEN TREASURER 1.00 X X 0 0 0 RON GRAU SECRETARY 1.00 X X 0 0 0 STEVE BISHKOFF DIRECTOR 1.00 X 0 0 0 MATTHEW KISELICA DIRECTOR 1.00 X 0 0 0 BEN LOCKSHIN MD DIRECTOR 1.00 X 0 0 0 EYAL OFIR DIRECTOR 1.00 X 0 0 0 ABBY VAN VORHEES MD DIRECTOR 1.00 X 0 0 0 NATE PAUL DIRECTOR 1.00 X 0 0 0 PETE MILLER DIRECTOR 1.00 X 0 0 0 JASON LICHTEN MD DIRECTOR 1.00 X 0 0 0 RICK SEIDEN DIRECTOR 1.00 X 0 0 0 MARK OBERMAN DIRECTOR 1.00 X 0 0 0 RANDY BERANEK PRESIDENT AND CEO 40.00 X 316006 0 28420 LEAH HOWARD CHIEF OPERATING OFFICER 40.00 X 196800 0 20149 EMILY BOYD CHIEF REVENUE OFFICER 40.00 X 186306 0 19394 BRIDGET HART DIRECTOR OF MAJOR GIFTS 40.00 X 145428 0 24950 BETTE DRAKE VP FINANCE AND OPERATIONS 40.00 X 119799 0 15541 PATRICK STONE VP ADVOCACY AND GOVERNMENT RELATIONS 40.00 X 116615 0 6759 KRISTINE BOCKMIER DIRECTOR OF FIELD OPERATIONS 40.00 X 115222 0 19213 1196176 0 134426 7 0 1 0 FAEGRE BAKER DANIELS LLP 1050 K STREET NW SUITE 400 WASHINGTON DC 20001 CONSULTING 278502 GMMB 3050 K STREET NW SUITE 100 WASHINGTON DC 20007 MARKETING CONSULTING 182258 PACIFIC MARKETING & PUBLISHING 2517 SE MAILWELL DR PORTLAND OR 97222 DIRECT MAIL FUNDRAISING 169975 LITHTEX PRINTING SOLUTIONS 6770 NE CENTURY BLVD HILLSBORO OR 97124 PRINTING 141988 CONVERO 835 SHARON DRIVE SUITE 200 CLEVELAND OH 44145 PUBLICATION DEVELOPMENT AND DISTRIBUTION 114046 5 105432 68470 2325457 10668948 28794 13168307 ADVERTISING INCOME 541800 1255184 1255184 CONFERENCE REGISTRATION 611710 13251 13251 CONSULTING 532000 3347 3347 1271782 124320 124320 3624311 3609877 1647 14434 -1647 12787 12787 0 2325457 364586 -364586 -364586 2644 0 2644 2644 14215254 19242 1255184 -227479 1801813 1801813 980000 980000 521916 390512 38190 93214 4281589 3203606 313295 764688 184794 138268 13522 33004 604595 452375 44240 107980 384425 287638 28129 68658 67694 55826 4391 7477 21710 21710 430252 430252 37805 37805 1175155 911609 83827 179719 18310 13426 4884 989600 367201 36952 585447 411238 352554 17333 41351 612698 343876 54293 214529 380054 303949 47504 28601 46166 34486 3370 8310 32437 24032 2425 5980 UBI TAXES 70683 70683 DUES AND SUBSCRIPTIONS 122428 91449 11620 19359 BAD DEBT 100350 100000 350 BANK FEES 76615 60633 15982 73310 43806 14656 14848 13425637 10226678 1004578 2194381 X 2110171 2916260 193248 2564575 3244767 377191 401037 12187 18573 135804 181795 432419 344782 95449 87637 5098000 5557511 30164 30164 10616789 12437744 754857 892661 1901114 2605000 12413 39550 250291 366529 2918675 3903740 X 3753855 7167604 3944259 1366400 7698114 8534004 10616789 12437744 789617 46273 0 X X 0 1 X 1 0 X 8705798 9161189 13602330 13408527 13168307 58046151 8705798 9161189 13602330 13408527 13168307 58046151 20710425 37335726 84329 76192 62020 89858 124320 436719 58482870 3361452 0.63840 0.63950 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 430252 430252 10803199 11233451 711673 177918 0 0 629898 684683 722412 711673 2748666 4122999 430866 415619 464205 430252 1740942 157475 171171 180603 177918 687167 1030751 17322 14388 14589 46299 19766 17697 2069 327555 264680 62875 85098 62405 22693 87637 DEFERRED RENT 110338 GIFT ANNUITY LIABILITY 41798 DEFERRED COMPENSATION 214393 366529 X 14223722 46273 46273 14177449 37805 37805 14215254 13387832 0 13387832 37805 37805 13425637 PART X, LINE 2: THE ORGANIZATION FOLLOWS THE PROVISION OF FASB ASC TOPIC OF ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND CONCLUDED THAT THERE ARE NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS TOPIC. 1 0 0 0 0 0 0 0 0 0 UNITED KINGDOM DISCOVERY GRANT 75000 WIRE SWITZERLAND DISCOVERY GRANT 75000 CHECK CANADA DISCOVERY GRANT 75000 CHECK AUSTRALIA DISCOVERY GRANT 75000 CHECK SWEDEN DISCOVERY GRANT 75000 WIRE CANADA EARLY CAREER RESEARCH GRANT 50000 CHECK BELGIUM EARLY CAREER RESEARCH GRANT 50000 WIRE CANADA EARLY CAREER RESEARCH GRANT 50000 CHECK CANADA PSORIATIC ARTHRITIS DIAGNOSTIC TEST GRANT 100000 CHECK CANADA FELLOWSHIP 50000 CHECK ITALY TRANSLATIONAL RESEARCH GRANT - 1ST YEAR 100000 WIRE DENMARK TRANSLATIONAL RESEARCH GRANT - 1ST YEAR 100000 WIRE ENGLAND TRANSLATIONAL RESEARCH GRANT - 2ND YEAR 100000 WIRE 13 9 0 0 0 0 0 0 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE VP OF RESEARCH PROGRAMS OF THE NATIONAL PSORIASIS FOUNDATION. X X X X X X 1 PACIFIC MARKETING & PUBLISHING 2517 SE MAILWELL DR MILWAUKIE OR 97222 DIRECT MAIL 0 336616 225421 111195 ARIA COMMUNICATIONS 717 WEST ST GERMAIN STREET ST CLOUD MN 56301 PHONE CAMPAIGN 0 64549 43226 21323 401165 268647 132518 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY TEAM NPF 1775959 1775959 12646 57089 172875 3300 SEATTLE GALA 549498 549498 48970 68206 1500 2325457 2325457 12646 106059 241081 4800 364586 -364586 SCHEDULE G, PART I, LINE 2B, COLUMN (V) EXPENSES ARE SEPARATELY ITEMIZED AND BILLED FROM FUNDRAISING FEES AND INCLUDE THE FOLLOWING: PRINTING 17,622 POSTAGE 103,835 PROF SVCS 7,828 ONLINE FUNDRAISING 491 SUPPLIES 2,345 MERCHANT FEES 5,840 MARKETING RESEARCH 12,470 1 UNIVERSITY OF CALIFORNIA DAVIS 2425 STOCKTON BOULEVARD SACRAMENTO CA 95617 946081352 501 (C)(3) 100000 BRIDGE GRANT UNIVERSITY OF CALIFORNIA LOS ANGELES PO BOX 957089 1125 MURPHY HALL 405 HILGARD AVENUE LOS ANGELES CA 90095 956006143 501 (C)(3) 100000 BRIDGE GRANT UNIVERSITY OF CINCINNATI 231 ALBERT SABIN WAY MSB 3408 CINCINATTI OH 45267 316000989 501 (C)(3) 75000 DISCOVERY GRANT UNIVERSITY OF MICHIGAN 7412 MEDICAL SCIENCE I 1301 E CATHERINE ST ANN ARBOR MI 481095675 386006309 501 (C)(3) 75000 DISCOVERY GRANT BRIGHAM AND WOMEN'S HOSPITAL HBTM ROOM 6002P 60 FENWOOD RD BOSTON MA 021156110 042312909 501 (C)(3) 75000 DISCOVERY GRANT UNIVERSITY OF PITTSBURGH 200 LOTHROP ST BST W1048 PITTSBURGH PA 15261 250965591 501 (C)(3) 75000 DISCOVERY GRANT NEW YORK UNIVERSITY 435 EAST 30TH ST SCIENCE BUILDING RM 414 NEW YORK NY 10016 135562308 501 (C)(3) 75000 DISCOVERY GRANT NATIONAL HEART LUNG AND BLOOD INSTITUTE (NIH) 10 CENTER DRIVE MSC 1454 BUILDING 10 MAGNUSON CC ROOM 5D-03 BETHESDA MD 20892 520858115 170 (C)(1) 75000 DISCOVERY GRANT NEW YORK UNIVERSITY SCHOOL OF MEDICINE 151 E 31ST ST APT 20K NEW YORK NY 10016 135562308 501 (C)(3) 50000 EARLY CAREER RESEARCH GRANT UNIVERSITY OF PITTSBURGH MEDICAL CENTER 200 LOTHROP ST W1028-3A BST PITTSBURGH PA 15217 250965591 501 (C)(3) 50000 EARLY CAREER RESEARCH GRANT UNIVERSITY OF UTAH 30 N 1900 E DEPARTMENT OF DERMATOLO Y SALT LAKE CITY UT 84132 876000525 501 (C)(3) 100000 PSORIATIC ARTHRITIS DIAGNOSTIC TEST GRANT UNIVERSITY OF CALIFORNIA SAN FRANCISCO 2340 SUTTER ST BOX 0808 N426 SAN FRANCISCO CA 941430808 946036493 501 (C)(3) 100000 PSORIATIC ARTHRITIS DIAGNOSTIC TEST GRANT UNIVERSITY OF ROCHESTER 601 ELMWOOD AVE BOX 695 ROCHESTER NY 14642 160743209 501 (C)(3) 100000 PSORIATIC ARTHRITIS DIAGNOSTIC TEST GRANT UNIVERSITY OF CALIFORNIA DAVIS PO BOX 989062 WEST SACRAMENTO CA 95798 946036494 501 (C)(3) 100000 PSORIATIC ARTHRITIS DIAGNOSTIC TEST GRANT NEW YORK UNIVERSITY SCHOOL OF MEDICINE 301 E17TH ST ROOM 1608 NEW YORK NY 10003 135562308 501 (C)(3) 100000 PSORIATIC ARTHRITIS DIAGNOSTIC TEST GRANT KECK SCHOOL OF MEDICINE OF UNIVERSITY OF SOUTHERN CALIFORNIA 346 N PALM DRIVE APT 2 BEVERLY HILLS CA 90210 951642394 501 (C)(3) 50000 FELLOWSHIP UNIVERSITY HOSPITALS 11100 EUCLID AVENUE BOLWELL SUITE 3100 CLEVELAND OH 44106 340714775 501 (C)(3) 50000 FELLOWSHIP UNIVERSITY OF PENNSYLVANIA 3400 CIVER CENTER BLVD PCAM SOUTH TOWER 7TH FLOOR OFFICE 775 PHILADELPHIA PA 19104 231352685 501 (C)(3) 50000 FELLOWSHIP UNIVERSITY OF CALIFORNIA DAVIS 3301 C STREET SUITE 1400 SACRAMENTO CA 95816 946081352 501 (C)(3) 50000 FELLOWSHIP NORTHWESTERN UNIVERSITY 676 N SAINT CLAIR STREET SUITE 1600 1600 CHICAGO IL 60611 362167817 501 (C)(3) 50000 FELLOWSHIP UNIVERSITY OF CALIFORNIA DAVIS 1 SHIELDS AVENUE DAVIS CA 95619 946036494 501 (C)(6) 100000 TRANSLATIONAL RESEARCH GRANT - 2ND YEAR THE MEDICAL COLLEGE OF WISCONSIN 8701 WATERTOWN PLANK ROAD MILWAUKEE WI 53226 390806261 501 (C)(3) 100000 TRANSLATIONAL RESEARCH GRANT - 2ND YEAR 21 1 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND FISCAL PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE SENIOR VP OF RESEARCH PROGRAMS OF THE NATIONAL PSORIASIS FOUNDATION. X X 0 1 0 1 0 0 0 0 0 RANDY BERANEK PRESIDENT AND CEO 301006 0 15000 0 0 0 13750 0 14670 0 344426 0 0 0 LEAH HOWARD CHIEF OPERATING OFFICER 196800 0 0 0 0 0 9840 0 10309 0 216949 0 0 0 EMILY BOYD CHIEF REVENUE OFFICER 186306 0 0 0 0 0 9314 0 10080 0 205700 0 0 0 BRIDGET HART DIRECTOR OF MAJOR GIFTS 145428 0 0 0 0 0 7271 0 17679 0 170378 0 0 0 PART I, LINE 4B THE CHIEF OFFICERS, REVENUE, EXECUTVE AND OPERATION HAVE A SPECIFIC AMOUNT ACCRUED EACH YEAR OF THE PAY. NOTHING WAS VESTED IN FY19. THE ACCRUALS WERE: CEO $30,000, COO $20,000 AND CRO $12,500 PART I, LINE 5 THERE IS AN INCENTIVE PLAN IN PLACE THAT INCLUDES 5% OF ANNUAL COMPENSATION TO EXECUTIVE TEAM MEMBERS SHOULD THEY REACH THE REVENUE GOAL AND ANOTHER 5% IF THEY MEET THEIR PERSONAL GOALS WHICH ARE NOT NECESSARILY REVENUE RELATED. ALL STAFF ARE INCLUDED IN THE INCENTIVE PLAN AT 2%. X 2 28794 SALE PRICE 0 1 1 PART I, LINE 32B: THE ORGANIZATION USES AN OUTSIDE COMPANY THAT RECEIVES DONATED AUTOMOBILES AND SELLS THEM ON BEHALF OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS EMAILED TO ALL BOARD MEMBERS FOR THEIR REVIEW PRIOR TO ITS BEING FILED ELECTRONICALLY WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C WE HAVE A CONFLICT OF INTEREST POLICY THAT IS SIGNED BY ALL DIRECTORS ANUALLY. ALL DIRECTORS AND KEY EMPLOYEES REFRAIN FROM VOTING OR COMMENTING ON ANYTHING WHERE THERE COULD BE A CONFLICT. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS ANNUALLY REVEIWS AND APPROVES THE CEO'S COMPENSATION. THE FOUNDATION UTILIZES AN INDEPENDENT COMPENSATION CONSULTANT AND SUBSCRIBES TO A SALARY SURVEY FOR COMPARABLE INFORMATION FOR SALARIES. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. AUDTIED FINANCIAL STATEMENTS ARE ALSO DISPLAYED ON THE WEBSITE. FORM 990, PART XII, LINE 2C: THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. SCHEDULE D, PART V, LINE 1 NOTE ON BOARD ENDOWMENT: THE BOARD DESIGNATED ENDOWMENT WAS DETERMINED BY THE BOARD TO NO LONGER BE REFLECTED AS A 'BOARD ENDOWMENT' BUT RATHER A CONTINGENY RESERVE TO FIRST AND FOREMOST COVER ANY HISTORICAL OPERATING DEFICIT AND SECONDARILY TO SERVE AS A SOURCE OF FUNDS THAT CAN BE RELEASED BY A MAJORITY VOTE OF THE BOARD, IN THE EVENT THAT FUTURE RESERVE AMOUNTS ARE NEEDED. AS SUCH, IT IS NO LONGER INCLUDED ON SCHEDULE D.